CDKN2A and meningioma: Across the four included investigations regarding meningioma patients with CDKN2A/B status and available PFS data, the pooled prevalence of CDKN2A/B deletion (hetero- or homozygous) was 0.049 (95% CI 0.040–0.057, see Fig. 2a).